Cargando…
Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy
PURPOSE: Intermittent androgen deprivation therapy is an effective treatment for metastatic prostate cancer. However, no study to date has evaluated the long-term outcomes of this treatment among patients with prostate cancer after radical prostatectomy. We retrospectively examined the treatment out...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967753/ https://www.ncbi.nlm.nih.gov/pubmed/29795595 http://dx.doi.org/10.1371/journal.pone.0197252 |
_version_ | 1783325648479059968 |
---|---|
author | Maru, Shintaro Uchino, Hideki Osawa, Takahiro Chiba, Satoshi Mouri, Gaku Sazawa, Ataru |
author_facet | Maru, Shintaro Uchino, Hideki Osawa, Takahiro Chiba, Satoshi Mouri, Gaku Sazawa, Ataru |
author_sort | Maru, Shintaro |
collection | PubMed |
description | PURPOSE: Intermittent androgen deprivation therapy is an effective treatment for metastatic prostate cancer. However, no study to date has evaluated the long-term outcomes of this treatment among patients with prostate cancer after radical prostatectomy. We retrospectively examined the treatment outcomes of patients with prostate-specific antigen recurrence who underwent radical prostatectomy at our department. MATERIALS AND METHODS: Of the 690 patients who underwent radical prostatectomy for local prostate cancer between 1988 and 2011, 129 patients who received androgen deprivation therapy for prostate-specific antigen recurrence were included in this study. Patient characteristics, luteinizing hormone-releasing hormone agonist administration, and outcomes were compared between the intermittent androgen deprivation group (n = 66) and the continuous androgen deprivation therapy group (n = 63). The non-recurrence and overall survival rates were compared between groups. RESULTS: Thirty-six patients (27.9%) experienced recurrence after luteinizing hormone-releasing hormone agonist administration. The 5-year non-recurrence rate and 10-year overall survival rate were higher in the intermittent group (92.9%) than in the continuous group (92.9 vs 57.9%, P < 0.001; and 95.9% vs 84.3%, P = 0.047, respectively). Furthermore, 63 patients (48.8%) showed a PSA nadir of less than 0.01 ng/mL after initiation of luteinizing hormone-releasing hormone agonist; among these patients, the non-recurrence rate was significantly higher in the intermittent androgen deprivation group (P = 0.003). CONCLUSIONS: Intermittent androgen deprivation therapy for prostate specific antigen recurrence after radical prostatectomy contributed to improvement of the non-recurrence rate and overall survival, and can be considered an effective therapy for better prognosis. |
format | Online Article Text |
id | pubmed-5967753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-59677532018-06-08 Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy Maru, Shintaro Uchino, Hideki Osawa, Takahiro Chiba, Satoshi Mouri, Gaku Sazawa, Ataru PLoS One Research Article PURPOSE: Intermittent androgen deprivation therapy is an effective treatment for metastatic prostate cancer. However, no study to date has evaluated the long-term outcomes of this treatment among patients with prostate cancer after radical prostatectomy. We retrospectively examined the treatment outcomes of patients with prostate-specific antigen recurrence who underwent radical prostatectomy at our department. MATERIALS AND METHODS: Of the 690 patients who underwent radical prostatectomy for local prostate cancer between 1988 and 2011, 129 patients who received androgen deprivation therapy for prostate-specific antigen recurrence were included in this study. Patient characteristics, luteinizing hormone-releasing hormone agonist administration, and outcomes were compared between the intermittent androgen deprivation group (n = 66) and the continuous androgen deprivation therapy group (n = 63). The non-recurrence and overall survival rates were compared between groups. RESULTS: Thirty-six patients (27.9%) experienced recurrence after luteinizing hormone-releasing hormone agonist administration. The 5-year non-recurrence rate and 10-year overall survival rate were higher in the intermittent group (92.9%) than in the continuous group (92.9 vs 57.9%, P < 0.001; and 95.9% vs 84.3%, P = 0.047, respectively). Furthermore, 63 patients (48.8%) showed a PSA nadir of less than 0.01 ng/mL after initiation of luteinizing hormone-releasing hormone agonist; among these patients, the non-recurrence rate was significantly higher in the intermittent androgen deprivation group (P = 0.003). CONCLUSIONS: Intermittent androgen deprivation therapy for prostate specific antigen recurrence after radical prostatectomy contributed to improvement of the non-recurrence rate and overall survival, and can be considered an effective therapy for better prognosis. Public Library of Science 2018-05-24 /pmc/articles/PMC5967753/ /pubmed/29795595 http://dx.doi.org/10.1371/journal.pone.0197252 Text en © 2018 Maru et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Maru, Shintaro Uchino, Hideki Osawa, Takahiro Chiba, Satoshi Mouri, Gaku Sazawa, Ataru Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy |
title | Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy |
title_full | Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy |
title_fullStr | Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy |
title_full_unstemmed | Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy |
title_short | Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy |
title_sort | long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967753/ https://www.ncbi.nlm.nih.gov/pubmed/29795595 http://dx.doi.org/10.1371/journal.pone.0197252 |
work_keys_str_mv | AT marushintaro longtermtreatmentoutcomesofintermittentandrogendeprivationtherapyforrelapsedprostatecancerafterradicalprostatectomy AT uchinohideki longtermtreatmentoutcomesofintermittentandrogendeprivationtherapyforrelapsedprostatecancerafterradicalprostatectomy AT osawatakahiro longtermtreatmentoutcomesofintermittentandrogendeprivationtherapyforrelapsedprostatecancerafterradicalprostatectomy AT chibasatoshi longtermtreatmentoutcomesofintermittentandrogendeprivationtherapyforrelapsedprostatecancerafterradicalprostatectomy AT mourigaku longtermtreatmentoutcomesofintermittentandrogendeprivationtherapyforrelapsedprostatecancerafterradicalprostatectomy AT sazawaataru longtermtreatmentoutcomesofintermittentandrogendeprivationtherapyforrelapsedprostatecancerafterradicalprostatectomy |